克拉斯
体内
药理学
癌症研究
药代动力学
医学
体外
癌症
化学
内科学
生物
生物化学
结直肠癌
生物技术
作者
J. Zhang,J. Lu,Z. Zheng,J. Lu,A. Wang,J. Wang,J. Chen,H. Rui,C. Chen,G. Chen
标识
DOI:10.1016/s0959-8049(22)00998-4
摘要
Background: Covalent inhibition of mutant KRAS G12C protein by locking this oncogenic driver in its inactive state is clinically efficacious. Sotorasib and adagrasib have improved overall response rates (ORR) and progression-free survival (PFS) in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC). However, achieving deeper and more durable responses remain as challenges in targeting KRAS G12C. Treatment of brain metastasis in NSCLC remains a high unmet medical need. D3S-001, currently in a phase 1 trial (NCT05410145), is designed to improve clinical outcomes by optimizing KRAS G12C target engagement (TE). Here we report its preclinical activity, selectivity, central nervous system (CNS) penetrant properties, and predicted target inhibition at dose levels under phase 1 study. Material and methods: The kinetics of KRAS G12C TE was measured by GTP-RAS ELISA in tumor cells and xenografts. Covalent adduct formation with KRAS G12C protein was confirmed by LC-MS. D3S-001 selectivity was assessed by free-cysteine proteomics. Anti-proliferative effect on cancer cells was evaluated by the CTG assay. Cancer cell line- and patient-derived xenografts were utilized for in vivo efficacy studies. D3S-001 pharmacokinetics (PK) in plasma and cerebrospinal fluid (CSF) were investigated in beagle dogs. Human target inhibition was calculated based on human PK prediction, free drug fraction, and in vitro TE data. Results: D3S-001 demonstrates >95% target inhibition in cells at 2 hours at 5 nM and >97% at 6 hours after a single dose of 30 mg/kg in NCI-H358 tumors. D3S-001 is highly selective with KRAS G12C being the only peptide identified by proteomic profiling. D3S-001 inhibits growth of KRAS G12C-mutant cell lines with low nanomolar IC50s while no activity is seen with non-KRAS G12C mutant cells. Daily oral administration of D3S-001 at 30 and 100 mg/kg led to complete and durable tumor regression in NCI-H358 NSCLC and CR6256 colorectal cancer models, respectively. D3S-001 demonstrates a CSF-to-plasma Kp,uu value of 0.33, comparable to those of adagrasib and approved CNS-active small molecule inhibitors. Importantly, observed CSF concentrations of D3S-001 are sufficient to achieve >95% KRAS G12C TE. In phase 1, D3S-001 dose will be escalated from 50 mg to 900 mg QD. Predicted human exposures at dose levels >100 mg QD are expected to consistently achieve >95% target inhibition. At dose levels >400 mg QD, predicted exposures should achieve >95% target inhibition in CNS. Conclusions: D3S-001 demonstrates rapid and near complete TE with KRAS G12C in vitro and in vivo. Its potency, selectivity, and CNS-penetrance support clinical development in patients with KRAS G12C mutation. Optimal TE predicted at clinical exposures may lead to deeper and more durable responses in both systemic and intracranial tumors than currently available KRAS G12C inhibitors. No conflict of interest.
科研通智能强力驱动
Strongly Powered by AbleSci AI